EF5 to Evaluate Tumor Hypoxia in Patients With High-Grade Soft Tissue Sarcoma or Mouth Cancer

Terminated 120 enrolled National Cancer Institute (NCI)

NaSingle-groupOpen-label

Summary

This laboratory study is using EF5 to evaluate tumor hypoxia in patients with high-grade soft tissue sarcoma or mouth cancer. Using the drug EF5 to measure the oxygen level in tumor cells may help in planning cancer treatment

Timeline

Start: 2001-08
Primary completion: 2007-09
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	EF5	Diagnostic / imaging agent	—	Intravenous

EF5 to Evaluate Tumor Hypoxia in Patients With High-Grade Soft Tissue Sarcoma or Mouth Cancer

Summary

Timeline

Drugs

Indications